What are the diagnosis, treatment options, and management strategies for carcinoid tumors in older adults?

Carcinoid Tumors: Diagnosis, Treatment, and Management in Older Adults

Overview and Classification

Carcinoid tumors are rare, slow-growing neuroendocrine neoplasms with an annual incidence of 1.35/100,000 for lung carcinoids and 0.02/100,000 for thymic carcinoids, with median age at diagnosis of 64 years for lung and 59 years for thymic tumors. 1

Key Anatomic Subtypes

• Bronchopulmonary carcinoids: Account for 25% of all neuroendocrine tumors and 1-2% of all lung cancers 1
• Thymic carcinoids: Extremely rare (0.02-0.18/100,000), predominantly affect men (3:1 ratio) 1
• Gastrointestinal carcinoids: Include gastric, duodenal, jejunal/ileal, appendiceal, and rectal subtypes 1

Histologic Grading (Critical for Prognosis)

• Typical carcinoid (TC): <2 mitoses per 10 high-power fields, no necrosis; 5-year survival 80% 1
• Atypical carcinoid (AC): 2-10 mitoses per 10 HPF with focal necrosis; 5-year survival 60% 1
• High-grade tumors: Thymic carcinoids have particularly poor prognosis with 5-year survival of 50% for low-grade and 0% for high-grade 1

---

Diagnostic Workup

Clinical Presentation

Up to 92% of patients are symptomatic at presentation with hemoptysis, cough, recurrent pulmonary infections, fever, chest discomfort, and unilateral wheezing. 1

Functional Syndromes (Critical to Recognize)

• Carcinoid syndrome: Occurs in only 2-8% of patients, typically requires liver metastases to bypass hepatic metabolism 1
• Cushing's syndrome: Present in 2% of bronchopulmonary carcinoids and one-third of thymic carcinoids, caused by ectopic ACTH production 1
• Carcinoid crisis: Can occur during bronchoscopic biopsy or surgical manipulation in previously asymptomatic patients 1

Essential Imaging Studies

Multiphase CT or MRI scans must be used for liver metastasis evaluation, as carcinoid tumors are highly vascular and can appear isodense with liver on single-phase CT. 1

• Chest/abdomen CT with IV contrast: Primary imaging modality 1
• Somatostatin receptor scintigraphy (Octreoscan or 68Ga-DOTATATE PET-CT): Recommended since 80% of typical carcinoids express somatostatin receptors 1
• Bronchoscopy: Required for bronchopulmonary carcinoids; use rigid bronchoscope for larger, more reliable biopsies with epinephrine solution to reduce bleeding risk 1
• FDG-PET: Often false-negative for well-differentiated carcinoids but may be positive in high-grade tumors 1

Biochemical Testing

Obtain chromogranin A levels in all patients with typical carcinoids, as plasma levels are typically elevated. 1

• 24-hour urine 5-HIAA: When carcinoid syndrome is suspected 1, 2
• Plasma ACTH and 24-hour urine cortisol: If Cushing's syndrome suspected 1
• Serum gastrin levels: For gastric carcinoids to differentiate types 1-3 1

Pathology Requirements

• Immunohistochemistry: Chromogranin A, synaptophysin, and NSE for neuroendocrine markers 1
• TNM staging: Use 8th edition UICC/AJCC for pulmonary carcinoids 1
• Lymph node assessment: Specify number and station of dissected nodes 1

---

Treatment of Localized Disease

Bronchopulmonary Carcinoids

Surgical resection is the primary curative therapy for pulmonary carcinoids, with approach dependent on size, location, and tissue type. 1

Surgical Options (in order of preference):

1. Bronchoscopic removal: For intraluminal typical carcinoids when feasible (combine bronchoscopic visualization with high-resolution CT) 1
2. Bronchial sleeve resection or segmentectomy: For tumors not meeting endobronchial resection criteria 1
3. Lobectomy or pneumonectomy: For larger or more invasive tumors 1

Non-Surgical Options:

• External radiotherapy: For symptomatic localized disease when surgery cannot be performed 1
• Endobronchial laser treatment: Palliative for airway obstruction, not curative 1

Thymic Carcinoids

Localized and locoregional thymic carcinoids require surgical resection, generally without adjuvant therapy. 1

Post-Resection Management:

• After incomplete resection: Radiation therapy alone is recommended 1
• Consider adding chemotherapy (category 3): Capecitabine or 5-fluorouracil at radiosensitizing doses, OR cisplatin/carboplatin with etoposide for atypical or poorly differentiated tumors 1

Gastric Carcinoids (Size and Gastrin-Dependent)

For hypergastrinemic patients with tumors ≤2 cm (types 1 and 2), options include endoscopic resection with biopsy, observation, or octreotide for Zollinger-Ellison syndrome patients. 1

• Tumors >2 cm: Endoscopic or surgical resection indicated 1
• Type 3 (normal gastrin, sporadic): Radical resection with regional lymphadenectomy due to aggressive behavior 1

Small Intestine/Colon Carcinoids

Surgical resection of bowel with regional lymphadenectomy is recommended, with careful examination of entire bowel for synchronous lesions. 1

• Consider prophylactic cholecystectomy: If future octreotide treatment anticipated, given association with gallstones 1

---

Management of Carcinoid Syndrome

First-Line Pharmacologic Treatment

Somatostatin analogues (octreotide or lanreotide) are the first-line treatment for carcinoid syndrome, providing effective control of flushing and diarrhea in 65-72% of patients while also serving as antiproliferative therapy. 2, 3

Initial Dosing:

• Octreotide LAR: 20-30 mg intramuscularly every 4 weeks 2
• Lanreotide: 120 mg deep subcutaneous every 4 weeks 2, 3
• Add short-acting octreotide: 150-250 mcg subcutaneously 3 times daily for first 10-14 days after initiating long-acting formulations 2

Dose Escalation for Inadequate Response:

• Octreotide LAR: Increase to 40 mg every 4 weeks or shorten interval to every 3 weeks 2
• Lanreotide: Increase to 120 mg every 3 weeks or consider 180 mg every 4 weeks 2

Critical Pre-Procedural Management (Prevent Carcinoid Crisis)

Administer IV octreotide 100-200 mcg bolus before any surgical or interventional procedure, followed by continuous infusion of 50 mcg/hour during the procedure. 2

• Continue infusion for 24 hours postoperatively, then wean slowly over 48 hours 2

Mandatory Cardiac Assessment

Obtain cardiology consultation and echocardiogram in all patients with carcinoid syndrome before initiating therapy, as 59% have tricuspid regurgitation. 2

• Highest risk: Urinary 5-HIAA >300 mcmol/24 hours and ≥3 flushing episodes daily 2

Adjunctive Symptom Management

• Persistent diarrhea: Add pancreatic enzyme supplements or cholestyramine 2
• Additional symptom control: Consider ondansetron 2

Second-Line Options

Add interferon-alpha 3-5 million units subcutaneously 3-5 times weekly when somatostatin analogues at maximum doses fail. 2

Tumor-Directed Therapy for Refractory Symptoms

Consider lutetium-177 DOTATATE for patients with somatostatin receptor-positive tumors on imaging who have refractory symptoms despite medical management. 2

---

Special Considerations for Older Adults (Age ≥72)

Pre-Treatment Assessment

• Performance status evaluation: Critical before intensive perioperative chemotherapy 4
• Comorbidity assessment: Cardiovascular disease particularly relevant given bradycardia risk with somatostatin analogues 1, 3
• Organ function testing: Renal and hepatic function affect dosing 3

Dosage Adjustments for Comorbidities

For acromegalic patients with moderate or severe renal impairment (CrCl <60 mL/min), start lanreotide at 60 mg every 4 weeks for 3 months. 3

For patients with moderate or severe hepatic impairment (Child-Pugh Class B or C), start lanreotide at 60 mg every 4 weeks for 3 months. 3

Cardiovascular Monitoring

Use somatostatin analogues with caution in patients at risk for bradycardia; decrease in heart rate may occur. 3

---

Monitoring and Follow-Up

Biochemical Monitoring

• 24-hour urinary 5-HIAA: At baseline and during treatment to assess biochemical response 2
• Chromogranin A levels: For monitoring disease progression 2
• Somatostatin receptor imaging: OctreoScan or 68Ga-DOTATATE PET-CT to assess receptor status and guide therapy selection 2

Surveillance for Complications

• Cholelithiasis: Monitor periodically; discontinue if complications suspected 3
• Glucose monitoring: Recommended with antidiabetic treatment adjustment as needed 3
• Thyroid function tests: Where clinically indicated, as decreases may occur 3
• Steatorrhea/malabsorption: Evaluate for pancreatic exocrine insufficiency if new onset or worsening symptoms 3

---

Multidisciplinary Care Requirement

The scarcity of lung and thymic carcinoids justifies therapeutic management by expert multidisciplinary teams in centers grouped within national or European networks for care and research optimization. 1